Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
SpringWorks Therapeuticsspringworkstx.com · Low evidenceSpringWorks Therapeutics is a biopharmaceutical company focused on developing targeted oncology treatments for rare cancers and devastating diseases. The company's late-stage programs include OGSIVEO (nirogacestat) for desmoid tumors and EZMEKLY (mirdametinib) for NF1-related plexiform neurofibromas, with ongoing research into BCMA combination therapies for multiple myeloma.
Parse Score